Botulinum toxin in the treatment of lingual movement disorders.
Identifieur interne : 001E74 ( Main/Exploration ); précédent : 001E73; suivant : 001E75Botulinum toxin in the treatment of lingual movement disorders.
Auteurs : Neema Kasravi [Canada] ; Mandar S. JogSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Anti-Dyskinesia Agents (therapeutic use), Antiparkinson Agents (adverse effects), Botulinum Toxins (therapeutic use), Female, Humans, Levodopa (adverse effects), Male, Middle Aged, Movement Disorders (complications), Movement Disorders (drug therapy), Movement Disorders (etiology), Parkinson Disease, Retrospective Studies, Time Factors, Tongue Diseases (chemically induced), Tongue Diseases (complications), Tongue Diseases (drug therapy).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemically induced : Tongue Diseases.
- complications : Movement Disorders, Tongue Diseases.
- drug therapy : Movement Disorders, Tongue Diseases.
- etiology : Movement Disorders.
- Aged, Female, Humans, Male, Middle Aged, Parkinson Disease, Retrospective Studies, Time Factors.
Abstract
Lingual movement disorders are a rare but serious manifestation of neurologic disease, which have the potential to cause significant morbidity. Traditionally, these disorders were treated with pharmacotherapy achieving only limited results. Several case series have demonstrated the effectiveness of Botulinum toxin injection for the management of focal lingual movement disorders; however, apprehension persists regarding intralingual injections due to the risk of dysphagia. Here, we report seven patients with lingual movement disorders treated with intralingual Botox (Allergan product) injections via a novel superior approach into the genioglossus over a period of 3 to 72 months. All patients experienced a marked improvement in their abnormal tongue movements with no substantial bleeding or dysphagia. Lingual Botulinum toxin injection should be considered a safe and viable treatment option for a variety of disorders affecting the tongue.
DOI: 10.1002/mds.22549
PubMed: 19795478
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E20
- to stream PubMed, to step Curation: 000E20
- to stream PubMed, to step Checkpoint: 000E20
- to stream Ncbi, to step Merge: 000B58
- to stream Ncbi, to step Curation: 000B58
- to stream Ncbi, to step Checkpoint: 000B58
- to stream Main, to step Merge: 002027
- to stream Main, to step Curation: 001E74
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin in the treatment of lingual movement disorders.</title><author><name sortKey="Kasravi, Neema" sort="Kasravi, Neema" uniqKey="Kasravi N" first="Neema" last="Kasravi">Neema Kasravi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19795478</idno><idno type="pmid">19795478</idno><idno type="doi">10.1002/mds.22549</idno><idno type="wicri:Area/PubMed/Corpus">000E20</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E20</idno><idno type="wicri:Area/PubMed/Curation">000E20</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E20</idno><idno type="wicri:Area/PubMed/Checkpoint">000E20</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E20</idno><idno type="wicri:Area/Ncbi/Merge">000B58</idno><idno type="wicri:Area/Ncbi/Curation">000B58</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B58</idno><idno type="wicri:Area/Main/Merge">002027</idno><idno type="wicri:Area/Main/Curation">001E74</idno><idno type="wicri:Area/Main/Exploration">001E74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Botulinum toxin in the treatment of lingual movement disorders.</title><author><name sortKey="Kasravi, Neema" sort="Kasravi, Neema" uniqKey="Kasravi N" first="Neema" last="Kasravi">Neema Kasravi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Botulinum Toxins (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (complications)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Parkinson Disease</term><term>Retrospective Studies</term><term>Time Factors</term><term>Tongue Diseases (chemically induced)</term><term>Tongue Diseases (complications)</term><term>Tongue Diseases (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Tongue Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Movement Disorders</term><term>Tongue Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Tongue Diseases</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease</term><term>Retrospective Studies</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lingual movement disorders are a rare but serious manifestation of neurologic disease, which have the potential to cause significant morbidity. Traditionally, these disorders were treated with pharmacotherapy achieving only limited results. Several case series have demonstrated the effectiveness of Botulinum toxin injection for the management of focal lingual movement disorders; however, apprehension persists regarding intralingual injections due to the risk of dysphagia. Here, we report seven patients with lingual movement disorders treated with intralingual Botox (Allergan product) injections via a novel superior approach into the genioglossus over a period of 3 to 72 months. All patients experienced a marked improvement in their abnormal tongue movements with no substantial bleeding or dysphagia. Lingual Botulinum toxin injection should be considered a safe and viable treatment option for a variety of disorders affecting the tongue.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></noCountry><country name="Canada"><noRegion><name sortKey="Kasravi, Neema" sort="Kasravi, Neema" uniqKey="Kasravi N" first="Neema" last="Kasravi">Neema Kasravi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19795478
|texte= Botulinum toxin in the treatment of lingual movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19795478" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |